Breaking News

Home Depot Says 56 Million Payment Cards at Risk From Hack
Tweet TWEET

Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open House

Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual
                    Meeting of Stockholders and Open House

PR Newswire

CARLSBAD, Calif., June 18, 2013

CARLSBAD, Calif., June 18, 2013 /PRNewswire/ --Isis Pharmaceuticals, Inc.
(NASDAQ: ISIS), the leader in antisense therapeutics, today announced that
management will present a general corporate update in conjunction with its
2013 Annual Meeting of Stockholders and Open House on Tuesday, June 25 at 2:10
p.m. Pacific Time in Carlsbad, CA.

The agenda for the meeting is as follows:
2:00 p.m. – 2:10 p.m. Annual Meeting of Stockholders (only for stockholders of
record as of April 26, 2013)
2:10 p.m. – 3:15 p.m. Corporate Presentation – Stanley T. Crooke, Isis'
Chairman and Chief Executive Officer
3:15 p.m. – 5:00 p.m. Scientific Poster Presentation and Open House

A live audio webcast of the presentation will be available on the "Investors &
Media" section of the Company's Web site, www.isispharm.com. A replay of the
presentation will be available on the Isis Web site within 48 hours and will
be archived for a limited time.

To RSVP to attend the meeting, please go to Isis' Home Page at
www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover
and develop novel drugs for its product pipeline and for its partners. Isis'
broad pipeline consists of 28 drugs to treat a wide variety of diseases with
an emphasis on cardiovascular, metabolic, severe and rare diseases, and
cancer. Isis' partner, Genzyme, is commercializing Isis' lead product,
KYNAMRO™, in the United States for the treatment of patients with HoFH.
Genzyme is also pursuing marketing approval of KYNAMRO in other markets.
Isis' patents provide strong and extensive protection for its drugs and
technology. Additional information about Isis is available at
www.isispharm.com.

SOURCE Isis Pharmaceuticals, Inc.

Website: http://www.isispharm.com
Contact: D. Wade Walke, Ph.D., Executive Director, Corporate Communications
and Investor Relations, 760-603-2741; Amy Blackley, Ph.D., Associate Director,
Corporate Communications, 760-603-2772
 
Press spacebar to pause and continue. Press esc to stop.